Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

Related Articles by Review for PubMed (Select 21852537)

1.

Validation of MdmX as a therapeutic target for reactivating p53 in tumors.

Garcia D, Warr MR, Martins CP, Brown Swigart L, Passegué E, Evan GI.

Genes Dev. 2011 Aug 15;25(16):1746-57. doi: 10.1101/gad.16722111.

2.

Mouse models of Mdm2 and Mdm4 and their clinical implications.

Xiong S.

Chin J Cancer. 2013 Jul;32(7):371-5. doi: 10.5732/cjc.012.10286. Epub 2013 Jan 18. Review.

3.

Mdmx and Mdm2: brothers in arms?

Marine JC, Jochemsen AG.

Cell Cycle. 2004 Jul;3(7):900-4. Epub 2004 Jul 2. Review.

4.

p53 regulation: teamwork between RING domains of Mdm2 and MdmX.

Wang X.

Cell Cycle. 2011 Dec 15;10(24):4225-9. doi: 10.4161/cc.10.24.18662. Epub 2011 Dec 15. Review.

PMID:
22134240
5.

Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4.

Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G.

Cell Death Differ. 2006 Jun;13(6):927-34. Review. No abstract available.

6.

Regulation of p53: a collaboration between Mdm2 and Mdmx.

Pei D, Zhang Y, Zheng J.

Oncotarget. 2012 Mar;3(3):228-35. Review.

7.

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.

Toledo F, Wahl GM.

Nat Rev Cancer. 2006 Dec;6(12):909-23. Review.

PMID:
17128209
8.

ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.

Meulmeester E, Pereg Y, Shiloh Y, Jochemsen AG.

Cell Cycle. 2005 Sep;4(9):1166-70. Epub 2005 Sep 29. Review.

9.

The p53 orchestra: Mdm2 and Mdmx set the tone.

Wade M, Wang YV, Wahl GM.

Trends Cell Biol. 2010 May;20(5):299-309. doi: 10.1016/j.tcb.2010.01.009. Epub 2010 Feb 19. Review.

10.

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Wade M, Wahl GM.

Mol Cancer Res. 2009 Jan;7(1):1-11. doi: 10.1158/1541-7786.MCR-08-0423. Review.

11.

Mdm2 and MdmX partner to regulate p53.

Wang X, Jiang X.

FEBS Lett. 2012 May 21;586(10):1390-6. doi: 10.1016/j.febslet.2012.02.049. Epub 2012 Mar 8. Review.

12.

MDMX: from bench to bedside.

Marine JC, Dyer MA, Jochemsen AG.

J Cell Sci. 2007 Feb 1;120(Pt 3):371-8. Review.

13.

Inhibitors of MDM2 and MDMX: a structural perspective.

Riedinger C, McDonnell JM.

Future Med Chem. 2009 Sep;1(6):1075-94. doi: 10.4155/fmc.09.75. Review.

PMID:
21425995
14.

MdmX regulates transformation and chromosomal stability in p53-deficient cells.

Matijasevic Z, Krzywicka-Racka A, Sluder G, Jones SN.

Cell Cycle. 2008 Oct;7(19):2967-73. Epub 2008 Oct 15. Review.

15.

MDM2 and MDM4: p53 regulators as targets in anticancer therapy.

Toledo F, Wahl GM.

Int J Biochem Cell Biol. 2007;39(7-8):1476-82. Epub 2007 Apr 8. Review.

16.

Functions of MDMX in the modulation of the p53-response.

Lenos K, Jochemsen AG.

J Biomed Biotechnol. 2011;2011:876173. doi: 10.1155/2011/876173. Epub 2011 Mar 22. Review.

17.

MDM2, MDMX and p53 in oncogenesis and cancer therapy.

Wade M, Li YC, Wahl GM.

Nat Rev Cancer. 2013 Feb;13(2):83-96. doi: 10.1038/nrc3430. Epub 2013 Jan 10. Review.

18.

Mdm2 and MdmX involvement in human cancer.

Berberich SJ.

Subcell Biochem. 2014;85:263-80. doi: 10.1007/978-94-017-9211-0_15. Review.

PMID:
25201200
19.

Regulation of MDM4.

Markey MP.

Front Biosci (Landmark Ed). 2011 Jan 1;16:1144-56. Review.

PMID:
21196223
20.

Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy.

Lu M, Miller P, Lu X.

FEBS Lett. 2014 Aug 19;588(16):2616-21. doi: 10.1016/j.febslet.2014.05.008. Epub 2014 May 17. Review.

PMID:
24844434
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk